RESUMEN
OBJECTIVE: To investigate the effectiveness of botulinum toxin in the salivary glands of patients with neurological impairment and drooling and its impact on the quality of life. MATERIALS AND METHODS: This systematic review was registered with the International Prospective Register of Systematic Reviews (CRD 42,023,435,242) and conducted using the Preferred Reporting Items for Systematic Reviews and Meta-analyses. An electronic search was performed in the PubMed/MEDLINE, Embase, Scopus, Cochrane Library, and clinical trial databases until August 2023, no language restriction. Cohort studies and randomized clinical trials of patients diagnosed with drooling and neurological impairment who used botulinum toxin on the salivary gland were included, which evaluated subjective quality of life parameters. The risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal Checklist and Risk of Bias 2 tools. The certainty of the evidence was analyzed using the Grading of Recommendations Assessment, Development, and Evaluation approach. RESULTS: Eight studies involving 317 patients were included. All studies, through subjective parameters, suggested the effectiveness of botulinum toxin in reducing drooling, resulting in an improvement in the quality of life. Three studies demonstrated improvements in swallowing and four in cases of respiratory diseases. Two clinical trials had a high risk of bias, whereas one had low risk. The five cohort studies that were evaluated had a high risk of bias. The certainty of the evidence was considered low. CONCLUSIONS: Based on the patient/caregivers' perception of improvement in drooling, dysphagia, and respiratory symptoms, it can be inferred that botulinum toxin application reduces subjective drooling in neurologically compromised patients. Its impact contributes to the general well-being and quality of life. CLINICAL RELEVANCE: Injection of botulinum toxin into the salivary glands can be considered an alternative technique to surgical or medicinal approaches in reducing drooling. It is effective, less invasive and without significant side effects. It promotes a positive impact on the well-being and quality of life of neurological patients.
Asunto(s)
Calidad de Vida , Sialorrea , Humanos , Toxinas Botulínicas/uso terapéutico , Toxinas Botulínicas Tipo A/uso terapéutico , Enfermedades del Sistema Nervioso/complicaciones , Fármacos Neuromusculares/uso terapéutico , Sialorrea/tratamiento farmacológicoRESUMEN
BACKGROUND: Despite the established efficacy of glycopyrronium bromide in reducing drooling among children with neurodevelopmental disabilities, evidence on its impact on the daily lives of children and parents and effectiveness in a real-world setting are scarce, especially among long-term users. This study explored timing and duration of glycopyrronium treatment, effect and impact on daily life, and occurrence of side effects to inform clinical practice. METHODS: This was a retrospective cohort study at a national referral centre for drooling, including 61 children with nonprogressive neurodevelopmental disabilities, treated with glycopyrronium for anterior and/or posterior drooling between 2011 and 2021. Data were obtained from medical records and supplemented by structured telephone interviews with parents. RESULTS: Anterior drooling severity decreased in 82% of the included children. Changes in the impact of drooling on burden of care, social interaction, and self-esteem were reported in 55%, 31%, and 36%, respectively. Side effects were noted for 71% of cases, yet only 36% of parents deemed these as outweighing the positive impact of treatment. A substantial majority (77%) of the included children were long-term users (≥6 months). Among these, 38% of parents reported decreasing effectiveness and 27% noticed more prominent side effects over time. CONCLUSIONS: Glycopyrronium demonstrated potential in mitigating the impact of drooling on daily life, although variations were observed in the specific aspects and extent of improvement. The real-world context of our study provides important insights for refining clinical practices, emphasizing the need for balanced consideration of treatment benefits and potential side effects to facilitate shared decision-making.
Asunto(s)
Glicopirrolato , Antagonistas Muscarínicos , Trastornos del Neurodesarrollo , Sialorrea , Humanos , Sialorrea/tratamiento farmacológico , Sialorrea/etiología , Glicopirrolato/uso terapéutico , Glicopirrolato/administración & dosificación , Niño , Masculino , Femenino , Estudios Retrospectivos , Trastornos del Neurodesarrollo/complicaciones , Preescolar , Antagonistas Muscarínicos/uso terapéutico , AdolescenteRESUMEN
OBJECTIVES: To describe the efficacy of atropine in controlling salivary flow in patients with sialorrhea or drooling. MATERIALS AND METHODS: We included randomized controlled studies, quasi-randomized trials, case reports, clinical trials, systematic reviews, and meta-analyses assessing the use of atropine in patients with sialorrhea or drooling. The endpoints were reduction in salivary flow rate, amount of saliva secreted, reduction in clinical symptoms of sialorrhea, death rattle intensity, or reduction in drooling intensity as measured by an objective scale such as the drooling intensity scale. RESULTS: A total of 56 studies with 2,378 patients were included in the systematic review. The underlying disease states included brain injury, amyotrophic lateral sclerosis, cerebral palsy, clozapine- and perphenazine-induced sialorrhea, Parkinson's disease, and terminal illness. The routes of atropine administration included sublingual, intravenous, subcutaneous, oral tablet or solution, and direct injection of atropine into parotid glands or at the base of the tongue. The generalized estimated equation regression models showed that sublingual administration is superior to oral and subcutaneous routes. CONCLUSION: Atropine is efficacious in managing sialorrhea in most disease states. Sublingual administration of atropine is superior to other routes of administration in reducing salivary flow in patients with sialorrhea.
Asunto(s)
Atropina , Sialorrea , Sialorrea/tratamiento farmacológico , Humanos , Atropina/uso terapéutico , Resultado del Tratamiento , Salivación/efectos de los fármacosRESUMEN
OBJECTIVE: To describe the current state of the art in the therapeutic administration of botulinum toxin with indications, efficacy, and safety profile for children and adolescents with cerebral palsy. DATA SOURCE: An integrative review was conducted. The MEDLINE/PubMed database was searched twice within the last decade using distinct terms, and only studies written in the English language were included. The study population was limited to those aged 0-18 years. Articles that were duplicates or lacked sufficient methodology information were excluded. DATA SYNTHESIS: We found 256 articles, of which 105 were included. Among the included studies, most were conducted in developed countries. Botulinum toxin demonstrated good safety and efficacy in reducing spasticity, particularly when administered by a multidisciplinary rehabilitation team. It is primarily utilized to improve gait and upper limb function, facilitate hygiene care, reduce pain, prevent musculoskeletal deformities, and even decrease sialorrhea in patients without a functional prognosis for walking. CONCLUSIONS: The administration of botulinum toxin is safe and efficacious, especially when combined with a multi-professional rehabilitation team approach, which increases the probability of functional improvement. It can also be beneficial for patients with significant functional impairments to help with daily care tasks, such as hygiene, dressing, and reducing sialorrhea. Pediatricians must be familiar with this treatment and its indications to attend to and refer patients promptly when necessary, and to exploit their neuroplasticity. Further research on this topic is required in developing countries.
Asunto(s)
Toxinas Botulínicas , Parálisis Cerebral , Fármacos Neuromusculares , Sialorrea , Niño , Adolescente , Humanos , Toxinas Botulínicas/uso terapéutico , Sialorrea/tratamiento farmacológico , Fármacos Neuromusculares/uso terapéutico , Parálisis Cerebral/tratamiento farmacológico , Espasticidad Muscular/tratamiento farmacológicoRESUMEN
Sialorrhea or drooling is a common problem in children and adults with neurodevelopmental disorders. It can negatively impact the quality of life due to its physical and psychological manifestations. Providers commonly prescribe atropine eye drops for topical administration to the oral mucosa, as an off-label treatment to manage sialorrhea. However, the off-label use of atropine eye drops can be associated with medication and dosing errors and systemic side effects. To address these limitations of treatment, we developed a mucoadhesive topical oral gel formulation of atropine as an alternative route to off-label administration of atropine eye drops. In this clinical pharmacokinetic (PK) study, we evaluated the safety and PK of atropine gel (0.01% w/w) formulation after single-dose administration to the oral mucosa in 10 healthy volunteers. The PK data showed that after topical administration to the oral mucosa, atropine followed a two-compartment PK profile. The maximum plasma concentration and area under the curve extrapolated to infinite time were 0.14 ng/mL and 0.74 h·ng·mL-1 , respectively. The absorption rate constant calculated by the compartmental analysis was 0.4 h-1 . Safety parameters, such as heart rate, blood pressure, and oxygen saturation, did not significantly change before and after administration of the gel formulation, and no adverse events were observed in all participants who received atropine gel. These data indicate that atropine gel formulation has a satisfactory PK profile, is well-tolerated at the dose studied, and can be further considered for clinical development as a drug product to treat sialorrhea.
Asunto(s)
Calidad de Vida , Sialorrea , Adulto , Niño , Humanos , Voluntarios Sanos , Sialorrea/tratamiento farmacológico , Área Bajo la Curva , Soluciones Oftálmicas/efectos adversos , Derivados de Atropina , Administración OralRESUMEN
OBJECTIVE: This retrospective review documents the experience of ipratropium bromide use among pediatric patients with sialorrhea at our multidisciplinary sialorrhea clinic at Children's Hospital at London Health Sciences Centre (LHSC). METHODS: A retrospective chart review of patients diagnosed with sialorrhea at our multidisciplinary clinic between January 2015 and June 2021 was completed. Data on patient demographics, comorbidities, clinical presentation, previous interventions, quality of life, and medication adverse side effects was collected. Drooling Frequency and Severity Scale (DFSS) scores were reviewed to compare sialorrhea management pre- and post-treatment with topical 0.03% ipratropium bromide nasal solution. A descriptive analysis and Wilcoxon signed rank tests were conducted to compare pre- versus post-treatment DFSS scores. RESULTS: A total of 12 patients presented for follow-up and were included in the final analysis. At the pre-treatment visit, the median DFSS score was 4 for frequency and 5 for severity. Post-treatment, median DFSS score was 3 for frequency and 4.5 for severity, (P = .020 and .129, respectively). Minimal adverse effects were encountered. CONCLUSIONS: Ipratropium bromide provided a statistically significant benefit for drooling frequency in the patients studied and may present an additional topical medical option for pediatric sialorrhea with limited adverse effects.
Asunto(s)
Ipratropio , Sialorrea , Humanos , Sialorrea/tratamiento farmacológico , Estudios Retrospectivos , Femenino , Masculino , Niño , Ipratropio/uso terapéutico , Ipratropio/administración & dosificación , Preescolar , Adolescente , Resultado del Tratamiento , Índice de Severidad de la Enfermedad , Calidad de Vida , Administración IntranasalRESUMEN
INTRODUCTION: Botox is frequently used for sialorrhea in patients with compromised airways and those with etiologies causing difficulty with secretion management (i.e. strokes, neurologic disorders, etc.). There are no published studies regarding the use of botulinum toxin (BoNT) in the neonate population. We aim to discuss our experience and safety of BoNT use in the neonate population in regards to alleviating secretion management and airway protection. METHODS: Retrospective review of neonates admitted to the neonatal intensive care unit (NICU) ≤12 months of age who received BoNT injection to submandibular (SMG) and parotid (PG) glands for sialorrhea/dysphagia. BoNT was administered under ultrasound (u/s) guidance by interventional radiology. RESULTS: 6 children were examined. 2 (33 %) were male. Avg NICU stay was 87.5 ± 33.1 days. 2 underwent surgical airway intervention prior to injection. Mean age at initial BoNT was 1.5 ± 0.7 months. Avg weight at injection was 4 ± 1.1 kg. Each PG and SMG were injected in 5/6 cases. Bilateral SMG were unidentified on u/s in 1 case and thus not injected. Dose range injected per gland was 5-15u. 100 % required tube feeds, 50 % with tubes distal to stomach (NJT/NDT). 83 % were completely NPO prior to injection and there was no noted clinical improvement in oral skills post injection. All had noted desats/apneas prior to injection and 83 % had reported decreased events post injection. 50 % had reported decrease O2 requirements and frequent suctioning 2wks after injection, however 2 (33 %) required surgical airway intervention after injection (trach, SGP/MDO). 4/6 (67 %) trialed medical therapy, anticholinergics being the most common. 50 % underwent 2nd injection (age = 6.5 ± 0.3 months) avg. 4.7 ± 0.7mo after 1st injection, and the same 3pts underwent 3rd injection (age = 12.5 ± 2.4 months) avg. 6.1 ± 2.5mo after 2nd injection. 1 pt. had a total 6 injections. There were no injection related complications. CONCLUSION: BoNT injection is a safe, non-invasive alterative for management of sialorrhea in neonates. Further extensive study needs to be performed to identify the optimal dose per gland in this population.
Asunto(s)
Toxinas Botulínicas Tipo A , Trastornos de Deglución , Sialorrea , Humanos , Sialorrea/tratamiento farmacológico , Sialorrea/etiología , Estudios Retrospectivos , Masculino , Femenino , Recién Nacido , Toxinas Botulínicas Tipo A/administración & dosificación , Trastornos de Deglución/tratamiento farmacológico , Trastornos de Deglución/etiología , Lactante , Resultado del Tratamiento , Glándula Submandibular , Glándula Parótida , Unidades de Cuidado Intensivo NeonatalRESUMEN
INTRODUCTION: Sialorrhea, also known as drooling, hypersalivation, or ptyalism, has a significant impact on the medical and psychosocial well-being of children. Onabotulinum toxin A (BoNT-A) is the most commonly used botulinum toxin worldwide for the treatment of sialorrhea in children. OBJECTIVES: To conduct a comprehensive systematic review and meta-analysis to assess the clinical efficacy and potential adverse effects of BoNT-A as a treatment for drooling in children. METHODS: Cochrane, Embase, and Medline databases were systematically searched (up to May 2023). Out of 535 identified publications, 20 were found eligible for inclusion. A systematic review and meta-analysis were performed to determine the efficacy of BoNT-A treatment in children in reducing the frequency and severity of drooling. RESULTS: Out of the 20 studies included, a meta-analysis was conducted on the complete dataset of eight studies involving 131 patients. BoNT-A was found to significantly decrease the severity of drooling in patients with sialorrhea (standardized mean difference [SMD], -2.07; 95% confidence interval [CI], -2.91 to -1.23; p < 0.0001) when compared with the conditions before injections using random-effects models. Six studies out of 20 reported dysphagia as an adverse effect after injection. Other side effects included thickness of saliva and pain at the site of injection. CONCLUSION: BoNT-A is a clinically effective therapy that improves drooling severity in children with sialorrhea. Although there were some adverse side effects reported, they were transient and not severe. Future studies are needed to further evaluate the best techniques and to identify the ideal dosages required to achieve the optimal outcomes. Laryngoscope, 134:3012-3017, 2024.
Asunto(s)
Toxinas Botulínicas Tipo A , Sialorrea , Humanos , Sialorrea/tratamiento farmacológico , Sialorrea/etiología , Toxinas Botulínicas Tipo A/administración & dosificación , Toxinas Botulínicas Tipo A/uso terapéutico , Niño , Fármacos Neuromusculares/administración & dosificación , Fármacos Neuromusculares/uso terapéutico , Fármacos Neuromusculares/efectos adversos , Resultado del Tratamiento , Preescolar , Adolescente , Masculino , FemeninoRESUMEN
AIM: To investigate the efficacy, safety, and impact on quality of life (QoL) of an oral formulation of 320 µg/mL glycopyrronium designed for children. METHOD: A double-blind, placebo-controlled SALIVA (Sialanar plus orAl rehabiLitation against placebo plus oral rehabilitation for chIldren and adolescents with seVere sialorrhoeA and neurodisabilities) trial was conducted. Children (3-17 years) with neurodisabilities and severe sialorrhoea (modified Teachers Drooling Scale ≥6) were randomized to 320 µg/mL glycopyrronium or placebo, in addition to non-pharmacological standard care. RESULTS: Of 87 participants, 44 were aged 10 years or under and 43 had cerebral palsy. The primary endpoint, change in total Drooling Impact Scale (DIS) score from baseline to day 84, was significantly greater (improved) with 320 µg/mL glycopyrronium versus placebo (median [quartile 1, quartile 3] -29.5 [-44.5, 0] vs -1 [-16, 5]; p < 0.001), an effect also observed at day 28 (median - 25 vs -2; p < 0.01). Significant reduction in bibs/clothes used per day was seen with glycopyrronium versus placebo at day 84 (median - 2 vs 0; p < 0.01). Glycopyrronium significantly improved DIS items 9 and 10 related to the extent that drooling affects the child's and family's life (p ≤ 0.03). Adverse events were reported by 77.3% and 69.8% of children with glycopyrronium and placebo respectively; the most common treatment-related adverse event was constipation (20.5% and 16.3%). INTERPRETATION: The formulation of 320 µg/mL glycopyrronium significantly improved drooling and reduced its impact on QoL, with good tolerability in children with neurodisabilities. WHAT THIS PAPER ADDS: The formulation of 320 µg/mL glycopyrronium significantly improved Drooling Impact Scale score versus placebo at day 84. The formulation reduced the impact of drooling on the child's and family's quality of life. There were no safety or tolerability concerns with this specific formulation.
Asunto(s)
Glicopirrolato , Calidad de Vida , Sialorrea , Humanos , Sialorrea/tratamiento farmacológico , Sialorrea/etiología , Niño , Glicopirrolato/uso terapéutico , Glicopirrolato/administración & dosificación , Método Doble Ciego , Masculino , Femenino , Adolescente , Preescolar , Antagonistas Muscarínicos/administración & dosificación , Antagonistas Muscarínicos/uso terapéutico , Parálisis Cerebral/complicaciones , Parálisis Cerebral/tratamiento farmacológico , Resultado del Tratamiento , Índice de Severidad de la EnfermedadRESUMEN
AIM: To develop robust multivariable prediction models for non-response to (1) submandibular botulinum neurotoxin A (BoNT-A) injections and (2) concurrent submandibular and parotid (four-gland) injections, to guide treatment decisions for drooling in children with neurodevelopmental disabilities, including cerebral palsy. METHOD: This was a retrospective cohort study including 262 children (155 males/107 females, median age 7 years 11 months [IQR 5 years 1 month], range 4 years 0 months - 17 years 11 months) receiving submandibular injections and 74 children (52 males/22 females, median age 7 years 7 months [IQR 4 years 3 months], range 4 years 9 months - 18 years 8 months) receiving four-gland injections. Multivariable logistic regression analyses were used to estimate associations between candidate predictors and non-response 8 weeks after injection. RESULTS: Ninety-six children (37%) were non-responders to submandibular injections, for which developmental age was the strongest predictor (adjusted odds ratio [aOR] 2.13; 95% confidence interval [CI] 1.02-4.45 for developmental age <4 years or 4-6 years with IQ <70). Other characteristics that showed a trend towards an increased risk of non-response were diagnosis, sex, and head position. Thirty-four children (46%) were non-responders to four-gland injections, for which tongue protrusion (aOR 3.10; 95% CI 1.14-8.43) seemed most predictive, whereas multiple preceding submandibular injections (aOR 0.34; 95% CI 0.10-1.16) showed a trend towards being protective. Predictors were, however, unstable across different definitions of non-response and both models (i.e. submandibular and four-gland) had insufficient discriminative ability. INTERPRETATION: Potential predictors of non-response to BoNT-A injections were identified. Nevertheless, the developed prediction models seemed inadequate for guidance of treatment decisions. WHAT THIS PAPER ADDS: Developmental age seemed most predictive of non-response to submandibular botulinum neurotoxin A injections. Non-response to concurrent submandibular and parotid injections was best predicted by tongue protrusion and number of previous injections. Multivariable prediction models including these clinical characteristics were unable to discriminate well. Predictors differed when non-response was defined using alternative outcome measures.
Asunto(s)
Toxinas Botulínicas Tipo A , Trastornos del Neurodesarrollo , Sialorrea , Glándula Submandibular , Humanos , Sialorrea/tratamiento farmacológico , Sialorrea/etiología , Masculino , Femenino , Toxinas Botulínicas Tipo A/administración & dosificación , Toxinas Botulínicas Tipo A/farmacología , Niño , Preescolar , Adolescente , Estudios Retrospectivos , Glándula Submandibular/efectos de los fármacos , Fármacos Neuromusculares/administración & dosificación , Fármacos Neuromusculares/farmacología , Parálisis Cerebral/complicaciones , Parálisis Cerebral/tratamiento farmacológico , Glándula ParótidaRESUMEN
PURPOSE: Clozapine, a second-generation antipsychotic medication, is mainly indicated for managing treatment-resistant schizophrenia. Among all the nonthreatening adverse effects of clozapine, sialorrhea is a stigmatizing complication occurring in approximately 31.0% to 97.4% of patients. In this study, 2 topical agents (atropine eye drop and ipratropium nasal spray) and a systemic medication (amitriptyline) were compared simultaneously for the management of clozapine-associated sialorrhea. METHODS: We conducted a randomized, single-blinded, non-placebo-controlled clinical trial from June 2022 to January 2023. Eligible patients were randomly allocated into 3 mentioned groups. Patients were monitored for sialorrhea weekly based on scales, including the Toronto Nocturnal Hypersalivation Scale, Clinical Global Impression-Improvement, and Clinical Global Impression-Severity for 1 month. Possible adverse drug reactions and adherence were also recorded. RESULTS: Twenty-four patients, including 6, 10, and 8 individuals in ipratropium bromide nasal spray, atropine eye drop, and amitriptyline groups, completed the study, respectively. The cohort's demographic, baseline clinical, and sociocultural characteristics were comparable among the 3 groups. Within-group comparisons, between times baseline and week 4, demonstrated that significant differences were in groups atropine and amitriptyline based on Toronto Nocturnal Hypersalivation Scale, in 3 groups based on Clinical Global Impression-Improvement, and also in only-atropine group based on Clinical Global Impression-Severity. Likewise, between-group comparisons showed that atropine was significantly more effective in clozapine-associated sialorrhea management than amitriptyline and ipratropium, in the first 2 weeks and second 2 weeks of study, respectively. Regarding safety, the interventions were tolerated relatively well. CONCLUSIONS: Conclusively, atropine is more efficacious than amitriptyline, within the first 2 weeks of study and also relative to ipratropium, overall. As time effect was significant between atropine and amitriptyline, according to analysis of covariance test, further investigation with longer follow-up duration would be prudent. In addition, expanding patient population with larger sample size should be conducted for more precision.
Asunto(s)
Antipsicóticos , Clozapina , Esquizofrenia , Sialorrea , Humanos , Amitriptilina/uso terapéutico , Antipsicóticos/efectos adversos , Atropina/uso terapéutico , Clozapina/efectos adversos , Ipratropio/uso terapéutico , Rociadores Nasales , Esquizofrenia/tratamiento farmacológico , Esquizofrenia Resistente al Tratamiento , Sialorrea/inducido químicamente , Sialorrea/tratamiento farmacológico , ComprimidosRESUMEN
This study aims to observe the therapeutic effect of Gushen Shetuo decoction on Parkinson's disease (PD), so as to provide reference for clinical practice. In order to demonstrate the clinical value of Gushen Shetuo Decoction, we selected 80 patients with PD for the study. Among them, 38 patients received the Gushen Shetuo decoction (research group), and 42 patients received Levodopa and Benserazide Hydrochloride Tablets (control group). There was no difference in Non-Motor Symptoms Scale (NMSS) scores between the research group and the control group (P>0. 05). However, the scores of motor complications in Movement Disorder Society-sponsored revision of the Parkinson's Disease Rating Scale (MDS-UPDRS) and those of Drooling Severity and Frequency Scale (DSFS) in the research group were lower than those in the control group (P<0. 05). Subsequently, we established PD model rats, and after Gushen Shetuo Decoction gavage treatment, we found that rats in the intervention group had increased mobility (P<0. 05), as well as notably improved pathological damage of substantia nigra and striatum. Also, the expression of PERK, ATF4 and CHOP in the brain tissues of rats in the intervention group was lower than those in the control group (P<0. 05). These results confirm that Gushen Shetuo decoction effectively improved the drooling of patients with PD and showed high safety.
Asunto(s)
Medicamentos Herbarios Chinos , Enfermedad de Parkinson , Sialorrea , Animales , Humanos , Ratas , Factor de Transcripción Activador 4 , Levodopa/uso terapéutico , Enfermedad de Parkinson/tratamiento farmacológico , Índice de Severidad de la Enfermedad , Sialorrea/complicaciones , Sialorrea/tratamiento farmacológico , Medicamentos Herbarios Chinos/uso terapéuticoRESUMEN
Introducción: La sialorrea es la pérdida involuntaria de saliva de la boca, ya sea debido a la producción excesiva de saliva o disminución de la frecuencia de deglución. Se habla de sialorrea patológica cuando persiste más allá de los 4 años de edad. Además de las implicaciones sociales, cambios de ropa frecuentes, puede provocar neumonías por aspiración y deshidratación. El manejo de la sialorrea requiere una evaluación completa con un enfoque de equipo multidisciplinario para el tratamiento, que incluye terapias no farmacológicas, farmacológicas y quirúrgicas. Objetivo: Presentar resultados quirúrgicos y farmacológicos en el tratamiento de sialorrea masiva. Material y Método: Se realizó revisión de historias clínicas de 7 pacientes portadores de sialorrea masiva. Todos los pacientes incluidos fueron refractarios a tratamiento médico. El diagnóstico fue obtenido por un equipo multidisciplinario. Se les realizó desfuncionalización quirúrgica y farmacológica de glándulas salivales. Se les aplicó Escala de Severidad (DSS) y escala de frecuencia (DFS), previo a cirugía y posterior a procedimiento hasta el año. Resultados: Mejoría clínica subjetiva posterior a desfuncionalización quirúrgica con disminución de DSS y DFS. Disminución promedio de baberos a 10/día. Conclusión: Los resultados obtenidos son buenos, si se consideran las escalas DSS, DFS y el número de baberos al día, que son mediciones tanto subjetivas y objetivas respectivamente.
Introduction: Massive Sialorrhea is the involuntary loss of saliva from the mouth, either due to excessive saliva production or decreased swallowing frequency. We speak of pathological sialorrhea when it persists beyond 4 years old. In addition to the social implications and frequent clothing changes. It can cause aspiration pneumonia and dehydration. Treatment for sialorrhea requires a comprehensive evaluation with a multidisciplinary team approach. Including non-pharmacological, pharmacological, and surgical therapies. Aim: Presentation of the results of surgical defunctionalization of the salivary glands plus injection of Botulinum Toxin in the treatment of massive sialorrhea. Material and Method: A review of the clinical records of 7 patients with massive sialorrhea was carried out. All included patients were refractory to medical treatment. The diagnosis was obtained by a multidisciplinary team. Surgical and pharmacological dysfunctionalization of salivary glands was performed. Severity Scale (DSS) and Frequency Scale (DFS) were applied before surgery and after the procedure up to a year. Results: Subjective clinical improvement after surgical defunctionalization with decreased SHD and DFS. Average decrease in bibs to 10/day. Conclusion: The evaluated strategy presented similar benefits with respect to the literature. The SHD and DFS scales and the number of bibs per day are both subjective and objective measurements, respectively, and allow the clinical improvement and quality of life of patients undergoing surgery to be evaluated individually.
Asunto(s)
Humanos , Masculino , Femenino , Preescolar , Niño , Adolescente , Glándulas Salivales/cirugía , Sialorrea/cirugía , Sialorrea/tratamiento farmacológico , Índice de Severidad de la Enfermedad , Epidemiología Descriptiva , Resultado del Tratamiento , Toxinas Botulínicas Tipo A/uso terapéuticoRESUMEN
A sialorreia/ptialismo é um sintoma não motor frequente da doença de Parkinson, que pode causar impacto na saúde e na qualidade de vida dos pacientes. O sintoma decorre da combinação da disfagia com disautonomia e, muitas vezes, também do efeito adverso de drogas frequentemente utilizadas no tratamento de sintomas da doença, como por exemplo, os antipsicóticos atípicos e os inibidores da acetilcolinesterase. Diversas opções terapêuticas são utilizadas na prática clínica para controle da sialorreia, dentre elas, drogas anticolinérgicas ou antagonistas dos receptores adrenérgicos, injeção de toxina botulínica, cirurgia, radioterapia e terapias comportamentais e fonoaudiológicas. Este trabalho faz uma revisão das propostas terapêuticas até o presente momento para controlar a secreção de saliva dos pacientes com doença de Parkinson. A injeção de toxina botulínica nas glândulas salivares guiada por ultrassom é a opção com mais evidência de eficácia e segurança, de acordo com os últimos estudos.
Sialorrhea is a frequent nonmotor symptom in Parkinson´s disease (PD) that influences the patients' health and quality of life. The symptom arises from a combination of difficulty in swallowing saliva, autonomic dysfunction or as a side effect of frequent used drugs to control symptoms of the disease, as for example, atypical antipsychotics and acetylcholinesterase inhibitors. In clinical practice, different therapeutic approaches are used to control sialorrhea, such as anticholinergic or beta adrenergic antagonistic drugs, botulinum toxin injection, surgery, radiotherapy, behavioral psychotherapy and speech therapy. This paper reviews the therapeutic options available until now to control the loss of saliva from PD patient. Botulinum toxin injection in the salivary glands guided by ultrasound shows the best efficacy and security profile, according to the last published data.
Asunto(s)
Humanos , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Enfermedad de Parkinson/complicaciones , Enfermedad de Parkinson/diagnóstico , Sialorrea/etiología , Sialorrea/tratamiento farmacológico , Toxinas Botulínicas/uso terapéutico , Glándula Parótida/efectos de los fármacos , Toxinas Botulínicas/administración & dosificación , Antagonistas Colinérgicos/uso terapéuticoRESUMEN
ABSTRACT Atropine sulfate blocks the muscarinic receptors in the salivary glands and leads to reduced saliva production. There are no published studies about its use in children with cerebral palsy. Objective To report the effect of sublingual atropine sulfate to treat drooling in children with cerebral palsy by comparing the results of the Drooling Impact Scale in a non-controlled open clinical trial. Results Twenty-five children were assessed. The difference in the mean scores of the pre- and post-treatment scales reached statistical significance. There was a low frequency of side effects compared to studies with other anticholinergics. Conclusion The use of sublingual atropine sulfate seems to be safe and there is a reduction in the Drooling Impact Scale score, which suggests efficacy in the treatment of drooling in children and adolescents with cerebral palsy. Our results should be replicated in randomized, placebo-controlled studies with larger numbers of participants.
RESUMO O sulfato de atropina bloqueia os receptores muscarínicos nas glândulas salivares reduzindo a produção de saliva. Não há estudos publicados relativos ao seu uso para tratamento da sialorreia em crianças com paralisia cerebral. Objetivo Relatar o efeito do sulfato de atropina sublingual no tratamento da sialorreia em crianças com paralisia cerebral a partir da comparação dos resultados da Drooling Impact Scale em ensaio clínico aberto não controlado. Resultados Vinte e cinco crianças foram avaliadas. A diferença das pontuações médias nas escalas pré-tratamento e pós-tratamento atingiu significância estatística. Houve baixa frequência de efeitos colaterais em relação a outros anticolinérgicos. Conclusão O uso de sulfato de atropina sublingual parece ser seguro e está relacionado a uma redução na pontuação da Drooling Impact Scale, o que sugere eficácia no tratamento da sialorreia em crianças com paralisia cerebral. Nossos resultados devem ser replicados em estudos randomizados, placebo controlados, com maior número de participantes.
Asunto(s)
Humanos , Masculino , Femenino , Preescolar , Niño , Adolescente , Atropina/administración & dosificación , Sialorrea/tratamiento farmacológico , Parálisis Cerebral/complicaciones , Antagonistas Muscarínicos/administración & dosificación , Atropina/efectos adversos , Sialorrea/etiología , Índice de Severidad de la Enfermedad , Administración Sublingual , Resultado del Tratamiento , Antagonistas Muscarínicos/efectos adversos , Relación Dosis-Respuesta a DrogaRESUMEN
ABSTRACT Amyotrophic lateral sclerosis is a progressive and fatal neurodegenerative disease characterized by the degeneration of motor neurons, which are the central nervous system cells that control voluntary muscle movements. The excessive salivation (sialorrhea) is present in approximately 50% of amyotrophic lateral sclerosis cases. Thus, some alternative therapeutic methods are sought, such as anticholinergic drugs and surgery. Recently the use of botulinum toxin applied at a midpoint of the salivary glands, often guided by ultrasound, have demonstrated positive results. The objective was to review the literature to demonstrate an alternative method to treatments of sialorrhea in patients with amyotrophic lateral sclerosis. In recent studies, the efficacy of botulinum toxin is confirmed, although new applications are required. Since the side effects are negligible, this is an alternative to treat amyotrophic lateral sclerosis, and other patients with diseases that present sialorrhea.
RESUMO Esclerose lateral amiotrófica é uma doença neurodegenerativa progressiva e fatal, caracterizada pela degeneração dos neurônios motores, as células do sistema nervoso central que controlam os movimentos voluntários dos músculos. A salivação excessiva (sialorreia) está presente em cerca de 50% dos casos de esclerose lateral amiotrófica. Dessa forma, surgem medidas terapêuticas alternativas como drogas anticolinérgicas e cirurgia, e recentemente, o uso da toxina botulínica, aplicada em um ponto central das glândulas salivares, muitas vezes guiado por ultrassonografia, demostrou resultados positivos. Objetivou-se revisar a literatura no intuito de demonstrar um método alternativo aos tratamentos de sialorreia em pacientes com esclerose lateral amiotrófica. Em estudos recentes, a eficácia do tratamento com toxina botulínica foi confirmada e, mesmo requerendo novas aplicações, os efeitos colaterais são ínfimos. Ela surge então como alternativa não só ao tratamento de esclerose lateral amiotrófica, mas também para outros pacientes com doenças que apresentem a sialorreia.
Asunto(s)
Humanos , Sialorrea/tratamiento farmacológico , Toxinas Botulínicas Tipo A/uso terapéutico , Esclerosis Amiotrófica Lateral/complicaciones , Fármacos Neuromusculares/uso terapéutico , Glándulas Salivales , Sialorrea/etiología , Resultado del Tratamiento , Ultrasonografía Intervencional , Inyecciones/métodosRESUMEN
Sialorrhea is a common oral motor impairment related to various neurological disorders such as cerebral palsy (CP), generating both physical and psychological complications that affect the quality of life of patients and their caregivers. Objective: To determine the clinical reduction of sialorrhea after injection with onabotulinumtoxin A (BTXA) in children diagnosed with CP. Methods: In 8 children 4-15 years of age, with GMFCS between II and V, injection with BTXA was performed in parotid and submandibular glands under ultrasound guidance. Measurement of salivation was made at baseline and 2, 4, 16, and 24 weeks post-infiltration through the Drooling Impact Scale (DIE), the Drooling Quotient (DQ) and the Drooling Severity and Frequency Scale (DSFS). Results: All children showed a significant reduction in salivation measured with the DQ (p < 0.002), the DIE (p < 0.002). Similarly, all children showed a 1 point reduction in the frequency subcomponent of the DSFS at 4 weeks post-injection. The severity subcomponent of DSFS showed a 1 point reduction only in the group of children with GMFCS II and IV. Conclusion: The use of BTXA in parotid and submandibular glands under ultrasound guidance is an effective intervention to reduce salivation, the severity and frequency of drooling, as well as the impact that sialorrhea has on patients and caregivers.
La sialorrea es consecuencia de una alteración motora oral frecuente en diversos trastornos neurológicos, como la parálisis cerebral (PC), generando complicaciones tanto físicas como psicosociales que impactan en la calidad de vida de los pacientes y sus cuidadores. Objetivo: Determinar la reducción clínica de sialorrea después de la infiltración de Onabotulinumtoxin A (BTXA) en niños con diagnóstico de PC. Pacientes y Métodos: En 8 niños de 4 a 15 años de edad, con GMFCS entre II y V, se realizó una infiltración con BTXA en glándulas parótida y submandibular bajo guía ecográfica. Se efectuó una medición basal de la salivación y en diferentes semanas post infiltración (2ª, 4ª, 8ª, 16ª y 24ª), a través de la Escala de Impacto de la Sialorrea (EIS), el Cociente de Salivación (DQ) y la Escala de Severidad y Frecuencia de la Sialorrea (DSFS). Resultados: Todos los niños presentaron una reducción significativa de la salivación en la evaluación con el DQ (p < 0,002) y la EIS (p < 0,002). En la DSFS en el subcomponente de frecuencia baja 1 punto posterior a la 4ª semana de infiltración en el total de los niños. En cambio, en el subcomponente de severidad baja 1 punto sólo en el grupo de GMFCS II y IV. Conclusión: El uso de BTXA en glándulas parótidas y submandibulares bajo guía ecográfica es un método de intervención efectivo para disminuir la salivación, la severidad y frecuencia de la sialorrea, así como el impacto que causa esta patología en los pacientes y cuidadores.
Asunto(s)
Humanos , Masculino , Adolescente , Femenino , Preescolar , Niño , Glándulas Salivales/fisiología , Parálisis Cerebral/complicaciones , Sialorrea/tratamiento farmacológico , Toxinas Botulínicas Tipo A/uso terapéutico , Salivación , Índice de Severidad de la Enfermedad , Sialorrea/etiologíaRESUMEN
Objetivo: Sistematizar as evidências científicas sobre a eficácia da toxina botulínica tipo A no tratamento da sialorréia. Método: A busca bibliográfica foi realizada através de uma pesquisa nas bases de dados PubMed Central Journals e Allergan Product Literature - botulinum toxin (APL) compreendendo o período dos últimos 10 anos, com os descritores: ?sialorrhea?, ?botulinum toxin?, ``treatment?, ?hypersalivation?, ?drooling?. A qualidade metodológica dos estudos foi avaliada pela Escala de Jadad. Resulados: Foram selecionados quatro estudos do tipo ensaio clínico randomizado duplo-cego. Os estudos selecionados mostram que as aplicações de toxina botulínica podem diminuir a sialorréia e suas consequências de forma satisfatória no que diz respeito à eficácia, além de não provocar efeitos adversos importantes. Assim, o tratamento com toxina botulínica tipo A pode apresentar-se como uma opção terapêutica possível para pacientes com sialorréia. Conclusão: Há necessidade de maior número de estudos, que sigam critérios de qualidade, para se chegar a uma conclus
Objective: To systematize scientific evidences about the efficacy of botulinum toxin type A for treatment of sialorrhea. Method: A bibliographic search was performed on the databases PubMed Central Journals and Allergan Product Literature - botulinum toxin (APL) encompassing articles published on the last 10 years containing the keywords: ?sialorrhea?, ?botulinum toxin?, ?treatment?, ?hypersalivation?, ?drooling?. The methodological quality of these articles was evaluated using the Jadad scale. Results: Four randomized, double-blind clinical trials were selected. The selected studies demonstrate that the application of botulinum toxin may satisfactorily reduce sialorrhea and its consequences, and it does not produce important adverse side effects. Therefore, treatment with botulinum toxin type A may be a possible therapeutic option in patients with sialorrhea. Conclusion: More studies with adequate quality are required form a definitive conclusion about the efficacy and safety of this procedure in patients with sialorrhea.
Asunto(s)
Humanos , Sialorrea/tratamiento farmacológico , Toxinas Botulínicas Tipo A/uso terapéutico , Análisis Costo-EficienciaRESUMEN
Drooling is defined as non-intentional salivary loss from mouth. Its presence may lead to functional, psychological and social impairments, which affect patients and caregivers as well. Anterior drooling, where salivary flow escapes from mouth to outside, affects social relations, constituting a physical contact barrier and having a negative impact on quality of life, and it also interfere on speech and communication. Posterior drooling, where salivary flow goes towards the throat is associated to severe swallowing disorders, being an important aspiration risk. Although drooling etiology is multifactorial, its often seen associated to a neuromuscular dysfunction. The approach to drooling should be made by a multidisciplinary team. Therapeutic approach could be non-pharmacologic, pharmacologic, systemic or local. Ultrasound guidance Botulinum toxin injection is an efficient and safe alternative. A 4-year-old male with posterior fossa astrocytoma, VI-XI CN impairment, prolonged mechanical ventilation and tracheostomy, swallowing disorder and hypersalivation is presented. Drooling management with botulinum toxin A injection in both parotid and submandibular glands under ultrasound guidance was performed, with an important salivary flow decrease, which allowed him to open his mouth without saliva loss, having a positive impact on communication and socialization, improving his quality of life as well.
La sialorrea se define como la pérdida no intencional de saliva desde la boca. Su presencia puede conducir a alteraciones funcionales, psicológicas y sociales, que afectan tanto al paciente como a sus cuidadores. La sialorrea anterior, donde la saliva es derramada desde la boca al exterior afecta la socialización, constituyéndose como una barrera para el contacto físico e impacta en forma negativa sobre la calidad de vida, además interfiere en el lenguaje, el habla y la comunicación. La sialorrea posterior que es derramada hacia del itsmo de las fauces, se asocia a trastornos severos de la deglución, constituyendo un riesgo importante de aspiración. Aún cuando la etiología de la sialorrea es multifactorial, frecuentemente la vemos asociada a una disfunción neuromuscular. Su abordaje debe ser realizado por un equipo multidisciplinario. El enfoque terapéutico puede ser, no farmacológico o farmacológico, sistémico o local. Una de las alternativas es la infiltración con toxina botulínica guiada en forma ecográfica que ha demostrado ser eficiente y segura. Se presenta el caso de un preescolar de 4 años con antecedente de astrocitoma de fosa posterior, compromiso de VI al XI pares craneanos, ventilación mecánica prolongada a través de traqueostomía, trastorno de deglución e hipersalivación secundaria. Se realiza el manejo de la sialorrea con toxina botulínica A en parótidas y glándulas submandibulares con marcación ecográfica, resultando una disminución importante del flujo de saliva que le permite abrir la boca sin escurrimiento. Lo anterior impacta positivamente en la comunicación y socialización, además de mejorar su calidad de vida.
Asunto(s)
Humanos , Masculino , Preescolar , Niño , Sialorrea/tratamiento farmacológico , Toxinas Botulínicas Tipo A/uso terapéutico , Grupo de Atención al Paciente , Respiración Artificial , Salivación , Índice de Severidad de la Enfermedad , Sialorrea/cirugía , Sialorrea/etiología , Factores de Tiempo , TraqueostomíaRESUMEN
OBJETIVO: Demonstrar o efeito da aplicação local Botox® em glândulas salivares de pacientes com diagnóstico de esclerose lateral amiotrófica (ELA), seguindo nosso protocolo institucional de tratamento da sialorréia de 2002. FORMA DE ESTUDO: Clínico prospectivo. MATERIAL E MÉTODO: Cinco pacientes com ELA avaliados na Clínica de Otorrinolaringologia da AACD (Associação de Assistência à Criança Deficiente) foram submetidos à aplicação tópica de Botox® nas glândulas salivares e acompanhados por um ano. O protocolo consiste num questionário clínico sobre as habilidades de deglutir saliva e as repercussões na qualidade de vida. Os pacientes deveriam ter tratamento odontológico prévio, intolerância aos efeitos adversos dos anti-colinérgicos, e ausência de aplicação de. Botox® em outros sítios por pelo menos seis meses. A aplicação foi guiada por ultra-sonografia para as glândulas submandibulares e a dose administrada foi de 30U em um ponto, e 20U em cada glândula parótida distribuída em dois pontos, após anestesia tópica com prilocaína. RESULTADOS: Cinco pacientes com ELA, com idade entre 45 e 59 anos foram submetidos ao tratamento de redução de saliva pela aplicação de Botox® em glândulas salivares. Nós observamos que os sintomas de sialorréia melhoraram dramaticamente em quatro pacientes. Três pacientes permaneceram quatro meses sem queixas, com acentuada melhora na qualidade de vida. Nenhum paciente apresentou efeitos colaterais locais ou sistêmicos com a aplicação de Botox® em glândulas salivares. Nós observamos que os sintomas de sialorréia melhoraram dramaticamente em quatro pacientes. Três pacientes permaneceram quatro meses sem queixas, com acentuada melhora na qualidade de vida. Nenhum paciente apresentou efeitos colaterais locais ou sistêmicos com a aplicação de Botox® em glândulas salivares.